Ponatinib: An oral tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphoblastic leuke.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- By:
- Publication type:
- Article
Works matching IS 1082801X AND DT 2013 AND VI 48 AND IP 5
Results: 12
1
2
New biologic Xeljanz Tofacitinib Pfizer.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- Publication type:
- Article
3
Medication reconciliation efforts meeting needs and showing promise.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- By:
- Publication type:
- Article
4
Little survival difference seen with kidney cancer agent.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- By:
- Publication type:
- Article
5
Glutamine, antioxidants: Don't offer to critically ill patients.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- Publication type:
- Article
6
FDA Drug Approvals.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- Publication type:
- Article
7
Efficacy of androgen receptor blockade in castration-resistant prostate Ca not dependent on age.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- By:
- Publication type:
- Article
8
Dietary fiber lowers risk of first stroke: Study.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- By:
- Publication type:
- Article
9
Care management programs key to helping deal with complexities of hepatitis C medication adherence.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- Publication type:
- Article
10
Anticoagulant use predicts survival in metastatic prostate cancer.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- By:
- Publication type:
- Article
11
[INFOGRAPHIC] Medication use in autism spectrum disorders: What is the evidence?
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- By:
- Publication type:
- Article
12
5-ARI does not affect prostate cancer mortality.
- Published in:
- Formulary, 2013, v. 48, n. 5, p. 1
- By:
- Publication type:
- Article